Parkinson's patients who take 'magic mushrooms' see key benefits, study finds
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience.
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience.
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Generate Key Takeaways
As Parkinson's cases continue to rise, the race is on for therapies to combat the effects of the disease — and researchers have pinpointed an unlikely source of relief.
Psilocybin, a psychedelic compound found in some mushrooms, has been found to improve mood, cognition and motor symptoms in Parkinson's patients, according to a new study from the University of California San Francisco (UCSF).
The substance, often referred to as "magic mushrooms," has previously been shown to alleviate depression and anxiety, which prompted the researchers to explore its potential for Parkinson's.
Psychedelic Retreat Reports 183% Spike In Bookings As Health Experts Cite 'Downside' Of Unregulated Use
People with the neurological movement disorder often suffer from "debilitating mood dysfunction" and don't tend to respond well to traditional antidepressants, according to a UCSF press release.
Psilocybin, a psychedelic compound found in some mushrooms, has been found to improve mood, cognition and motor symptoms in Parkinson's patients.
"Many people don't realize this, but mood symptoms in Parkinson's are linked to a faster physical decline," said lead study author Ellen Bradley, M.D., assistant professor and associate director of UCSF's Translational Psychedelic Research Program, in the release.
Read On The Fox News App
"And they are actually a stronger predictor of patients' quality of life with Parkinson's than their motor symptoms."
The small study included 12 people with mild to moderate Parkinson's disease. They ranged in age from 40 to 75. All had depression and/or anxiety.
Fda Rejects Mdma As Psychedelic-based Treatment For Mental Health, Ptsd
They all received a 10 mg-dose of psilocybin, then a 25 mg-dose two weeks later. To measure the effects, the participants met with a licensed therapist before and after receiving the medication.
At the one-week and one-month follow-ups, the patients reported "clinically significant improvements" not only in mood and cognition, but also motor function.
"These results are really encouraging," Bradley told Fox News Digital. "Depression and anxiety, which debilitate so many people with Parkinson's, improved significantly — and those improvements lasted for at least three months after patients took the drug."
Amir Inamdar, a pharmaceutical physician in the U.K. and chief medical officer at Cybin, noted that the improvement in motor symptoms was somewhat surprising.
"As the authors note, this could be because of the modulation of dopamine via psilocybin's effect on several serotonin receptor types." (Inamdar was not involved in the study.)
The most common side effects of psilocybin were anxiety, nausea, headache and elevated blood pressure, but none were serious enough to require medical care, according to the researchers.
People with the neurological movement disorder often suffer from "debilitating mood dysfunction" and don't tend to respond well to traditional antidepressants.
"Despite the reports of challenging experiences in a couple of participants, psilocybin seemed to be well-tolerated," Inamdar noted. "The side effects were consistent with what has been seen in other studies, with no precipitation/ exacerbation of psychotic symptoms."
The study, which was published in Neuropsychopharmacology, a Nature publication, was funded by an anonymous donor.
This was the first study to measure the effects of a psychedelic substance on patients with a neurodegenerative disease, according to USCF.
While this study was an "important first step," Bradley noted that the researchers can't draw conclusions from it, as it was a small pilot without a control group.
"We've now started a much larger trial designed to rigorously test if psilocybin is effective in Parkison's," she told Fox News Digital.
"We're also collecting multimodal biological data to understand how psilocybin works. That's critical not just for optimizing psilocybin treatments, but also for guiding development of next-generation psychedelics that are in the pipeline now and could be promising for people with Parkinson's."
Click Here To Sign Up For Our Health Newsletter
Bradley still recommends that Parkinson's patients approach psilocybin and other psychedelics with "a lot of caution."
"I wouldn't recommend to my patients with Parkinson's that they start using psilocybin," she clarified. "We're very, very early in this research, and we don't think these drugs will be safe for everyone with the illness."
This was the first study to measure the effects of a psychedelic substance on patients with a neurodegenerative disease, according to USCF.
"I hope that people continue to advocate for research so we can speed this process of identifying the right psychedelic treatment for the right patient at the right time."
Inamadar agreed that while the results are encouraging, the study was based on a small and limited sample.
For more Health articles, visit www.foxnews.com/health
"The study was also open-label, which lends itself to higher expectancy effects, though the improvements in mood and anxiety symptoms were still seen at three months," he added.
"Overall, [the] quite encouraging results warrant further investigation, certainly in trying to understand the mechanism behind improvement in motor symptoms."
Original article source: Parkinson's patients who take 'magic mushrooms' see key benefits, study finds
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
3 hours ago
- Yahoo
US appeals court confirms patent validity of Acadia's Parkinson's drug
(Reuters) -Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, its drug for hallucinations and delusions associated with Parkinson's disease. The decision supports a December 2023 ruling from the U.S. District Court of Delaware, ensuring the patent remains protected in Acadia's legal battle against India-based drugmaker MSN Laboratories. The appeals court followed a precedent that says an earlier patent claim cannot be invalidated by a later one if they share the same priority date. "We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for Nuplazid, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for Nuplazid 34 mg capsule formulation into 2038," said CEO Catherine Owen Adams. This decision comes after another favorable ruling for Acadia regarding its formulation patent for Nuplazid. The court supported Acadia's claims of infringement and validity in its legal case against Aurobindo Pharma and other companies. The U.S. FDA approved Nuplazid for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis in 2016.


Gizmodo
5 hours ago
- Gizmodo
These U.S. States Have the Highest Rates of Dementia
Your zip code may shape your aging brain's health. New research out today shows that people's odds of being diagnosed with dementia differ significantly across different parts of the U.S. Scientists at the University of California, San Francisco, led the study, published Monday in JAMA Neurology. They analyzed the medical records of veterans, finding that dementia rates were noticeably higher in the Southeast, Northwest, and other regions, even after accounting for some possible factors like income. The findings suggest that deep-seated regional differences can contribute to dementia risk, the researchers say. Dementia is a growing public health issue, particularly among the elderly. More than 6 million Americans are living with dementia currently and a government-funded study this February projected that 42% of Americans over 55 will develop it in their lifetime. It's a complex condition, with most cases caused by a mix of environmental and/or genetic factors. But according to senior study author and neurologist Kristine Yaffe, there's been little research looking at how the risk of dementia can vary geographically, at least on a national level. Yaffe and her team had access to a dataset that had the potential to shed light on that: deidentified records from people enrolled in the Veterans Health Administration, the largest integrated healthcare system in the U.S. 'We realized the VA national data would allow for such an investigation as the VA has a uniform way of capturing data across the U.S.,' Yaffe, who is also chief of neuropsychiatry at the San Francisco VA healthcare system, told Gizmodo in an email. 'There are no other national healthcare systems that have this.' Yaffe's team studied the health of more than 1.2 million randomly selected VA patients 65 years and older who had no pre-existing dementia. These people were followed for an average length of 12 years. After adjusting for age, dementia rates were lowest in the Mid-Atlantic region, covering states like Pennsylvania, Maryland, and Virginia. Using this as a baseline, the researchers found that dementia rates were 25% higher in the Southeast (Kentucky, Tennessee, and Alabama); 23% higher in both the Northwest (Idaho, Oregon, and Washington) and the Rocky Mountains (Colorado, Montana, and the Dakotas); 18% higher in the South (Texas, New Mexico, and Louisiana); 13% higher in the Southwest (California, Nevada, and Arizona); and 7% in the Northeast (New York). 'This is a very large difference, especially given that these are all veterans with care at the VAHS,' Yaffe said. 'It was really surprising we saw such big differences.' The researchers reasoned that factors such as a person's average level of education, how rural a state was, or the rate of other health conditions like heart disease within these states might explain most of the variance they found. But even when they adjusted for these variables, the patterns barely budged at all. That could mean there are other reasons—reasons not so easily captured through medical records alone—why someone in New Jersey will tend to have a lower risk of dementia than a similar person in Kentucky. 'It's possible that the differences are explained by lifelong differences in things like education quality (vs quantity) and social determinants of health might be driving some of the differences,' Yaffe said. The findings now leave open more questions to be answered, which the team plans to start digging into. With any luck, the lessons they learn might help us find new ways to better prevent dementia.
Yahoo
5 hours ago
- Yahoo
IBM all-time high, Universal Health falls, Topgolf Callaway rises
Market Domination co-host Yahoo Finance host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. IBM (IBM) stock hit an all-time high and surpassed a $250 billion market cap. Universal Health Services (UHS) stock is under pressure after the company presented at the Goldman Sachs Global Healthcare Conference. Topgolf Callaway (MODG) stock is surging after a board member purchased $2.5 million in shares last week. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. It's time for Yahoo! Finance's market minute. Shares of IBM hitting all-time highs on Monday. The stock also surpassing a market cap of $250 billion for the first time in the company's history. That move in the stock coming amid recent acquisitions, helping the company enter the high-growth software and services space. Universal Health Services under pressure following its presentation at the Goldman Sachs Global Healthcare Conference. The company's CFO, Steve Filton, saying labor shortages have impacted staffing and subacute facilities, according to Bloomberg. Filton also noted that the length of stay for patients is still higher than pre-COVID levels. Shares of Topgolf Callaway Brands surging in today's session, a securities filing showing that a board member purchased about $2.5 million worth of shares last week. The purchase signaling a boost of confidence in the tech-enabled golf company. And that's your Yahoo! Finance market minute. For more on what's trending on Yahoo! Finance, scan the QR code below. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data